MUNICH — For the first time in a controlled trial, meaningful clinical benefit has been achieved with a drug in nonobstructive hypertrophic cardiomyopathy, a disease for which so far there have been no approved therapies. Aficamten, which is already approved for obstructive hypertrophic cardiomyopathy, showed significant benefit for dual primary endpoints of reduced symptom burden …
Read More
Drug Benefit Seen in Nonobstructive HCM
